

Discovering novel approaches for early detection,
targeted therapies, and personalized medicine.

“These mutations are important because mutated
genes can be targets for anti-cancer therapy.”

Dr. Meyerson

The Caring for Carcinoid Foundation selected this project to revolutionize the diagnosis and treatment of carcinoid and related NET patients. Matthew Meyerson, M.D., Ph.D., will conduct the first large-scale genomic study for oncogene discovery in carcinoid. Renowned researcher Dr. Matthew Meyerson is the Director of the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute, and an Associate Professor of Pathology at Harvard Medical School. Dr. Meyerson's laboratory focuses on discovering cancer genome alterations using technology and expertise at the Broad Institute and the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute.

CFCF selected Dr. Meyerson's proposal for this project because he and his team of collaborators have consistently been at the forefront of genomics. Dr. Meyerson's laboratory has recently discovered candidate oncogenes for lung adenocarcinoma as part of the “Tumor Sequencing Project,” and those for glioblastoma as part of the “Cancer Genome Atlas.” Just as Dr. Meyerson said of his Tumor Sequencing Project, so too here he says, “Our study could achieve a real impact on the care of carcinoid patients.”



Using the most powerful methods available, Dr. Meyerson and his team will identify which genes are altered in carcinoid and then compare these genes' sequences to genes from normal tissue. The team will determine which of these genes are oncogenes and are likely to cause tumor growth. Identifying these oncogenes can lead to the development of new targeted therapies to block or inhibit tumor growth.

Ultimately, this study may lead to new therapies “personalized” to each patient's specific mutations, as well as earlier detection and diagnosis, and strategies for prevention.

Your dollars devoted to this project help us all get closer to a cure for carcinoid cancer. Every day, we make tangible and measurable progress. Together, we will end the suffering of carcinoid patients. If you would like to help give carcinoid patients hope and a better future, and for more information on how to join us in this important campaign for a cure, please visit: www.caringforcarcinoid.org.